{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "52-year-old female diagnosed with bone metastatic EGFR L858R-mutated NSCLC in July 2019. Never smoker and without previous medical history.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0006123",
              "label": "bone metastasis",
              "status": "active",
              "onset_date": "2019-07"
            },
            {
              "code": "C4021922",
              "label": "EGFR L858R-mutated NSCLC",
              "status": "active",
              "onset_date": "2019-07"
            }
          ],
          "social_history": [
            {
              "category": "smoking",
              "status": "never"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Gefitinib (250 mg daily) was administered starting around July 2019 without any adverse event.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Gefitinib",
              "dosage": "250 mg",
              "frequency": "daily",
              "modality": "oral",
              "start_date": "2019-07",
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "In June 2020, the patient developed intracranial hypertension symptoms including headache, diplopia, and vomiting. CSF analysis in June 2020 showed hyperproteinorachia (0.49 g/L) and adenocarcinomatous cells (4%).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0002734",
              "label": "Intracranial Hypertension",
              "status": "active",
              "onset_date": "2020-06"
            }
          ],
          "HPI": [
            {
              "summary": "Developed intracranial hypertension symptoms",
              "onset": "2020-06",
              "associated_symptoms": [
                "C0018681",
                "C0012569",
                "C0042963"
              ]
            }
          ],
          "labs": [
            {
              "test": "Hyperproteinorachia",
              "value": "0.49",
              "unit": "g/L",
              "flag": "abnormal",
              "timestamp": "2020-06"
            },
            {
              "test": "Adenocarcinomatous cells",
              "value": "4",
              "unit": "%",
              "flag": "abnormal",
              "timestamp": "2020-06"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Bone metastases and primary lung lesion did not progress. Molecular analysis identified EGFR L858R mutation without acquired T790M mutation in plasmatic and CSF analysis.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C79.51",
              "label": "Secondary malignant neoplasm of bone",
              "status": "active"
            },
            {
              "code": "C34",
              "label": "Primary lung lesion",
              "status": "active"
            }
          ],
          "labs": [
            {
              "test": "EGFR L858R mutation",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "T790M mutation",
              "value": "negative",
              "unit": null,
              "flag": "normal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Osimertinib (80 mg daily) was started as a second-line treatment in combination with nineteen intrathecal methotrexate injections (15 mg biweekly). Treatment with Osimertinib and intrathecal methotrexate was well tolerated and led to neurological improvement with disappearance of tumor cells in CSF and normalization of proteinorachia.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1705932",
              "dosage": "80 mg",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0025312",
              "dosage": "15 mg",
              "frequency": "biweekly",
              "modality": "intrathecal",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "procedures": [
            {
              "name": "C0025312",
              "approach": "other",
              "date": null,
              "location": "intrathecal",
              "performed_by": null,
              "outcome": "C0205048"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "In October 2021, neurological symptoms reappeared including cerebellar ataxia, diplopia, headaches and dysarthria. CSF analysis confirmed progression of carcinomatous meningitis and high proteinorachia (8.66 g/L). Bone and lung lesion did not progress.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C79.31",
              "label": "Secondary malignant neoplasm of brain and cerebral meninges from other primary site",
              "status": "active",
              "onset_date": "2021-10"
            }
          ],
          "HPI": [
            {
              "summary": "Neurological symptoms reappeared including cerebellar ataxia, diplopia, headaches and dysarthria.",
              "onset": "2021-10",
              "progression": "sudden",
              "associated_symptoms": [
                "C0007758",
                "C0013067",
                "C0018681",
                "C0013432"
              ]
            }
          ],
          "labs": [
            {
              "test": "C0235350",
              "value": "8.66",
              "unit": "g/L",
              "flag": "abnormal",
              "timestamp": "2021-10"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initiation of Gefitinib treatment."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Development of intracranial hypertension symptoms and abnormal CSF analysis.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0018681",
            "C0012569",
            "C0042963"
          ],
          "change_type": "progression",
          "target_domain": "symptom",
          "timestamp": "2020-06"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Assessment of disease progression and molecular analysis.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C4021922"
          ],
          "change_type": "other",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Initiation of Osimertinib and intrathecal methotrexate treatment, leading to neurological improvement.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1705932",
            "C0025312"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Reappearance of neurological symptoms and confirmation of carcinomatous meningitis progression.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0007758",
            "C0013067",
            "C0018681",
            "C0013432"
          ],
          "change_type": "progression",
          "target_domain": "symptom",
          "timestamp": "2021-10"
        }
      }
    }
  ]
}